Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoki Hashimoto

Showing results (221-230 of 249) with videos related to

Pageof 25
Sort By:
Sleep Medicine|December 7, 2021
Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide studyRyuji Furihata, Rei Otsuki, Naomi Hasegawa, et al.
Bjpsych Open|November 20, 2018
Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorderIchiro Kusumi, Yuki Arai, Ryo Okubo, et al.
BMC Psychiatry|June 28, 2023
Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment projectNaoki Hashimoto, Norio Yasui-Furukori, Naomi Hasegawa, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 6, 2026
Optimizing multi-site schizophrenia differentiation: MRI harmonization with 20 controls per scanner in a study of 3560 subjects across 15 MRI scannersNaoki Hashimoto, Kiyotaka Nemoto, Masaki Fukunaga, et al.
Neuropsychopharmacology Reports|July 1, 2020
Prescription patterns in patients with schizophrenia in Japan: First-quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" projectKayo Ichihashi, Hikaru Hori, Naomi Hasegawa, et al.
The International Journal of Neuropsychopharmacology|June 20, 2022
Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide StudyShinichiro Ochi, Hiromi Tagata, Naomi Hasegawa, et al.
Biological Psychiatry|February 16, 2016
Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese PopulationTakeo Saito, Masashi Ikeda, Taisei Mushiroda, et al.
Neuropsychopharmacology Reports|November 29, 2022
Satisfaction with web-based courses on clinical practice guidelines for psychiatrists: Findings from the "Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)" projectHitoshi Iida, Tsuyoshi Okada, Kiyotaka Nemoto, et al.
Asian Journal of Psychiatry|January 20, 2022
The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE projectKayo Ichihashi, Yoshitaka Kyou, Naomi Hasegawa, et al.
Journal of Clinical Psychopharmacology|May 22, 2023
Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in JapanToshiaki Onitsuka, Tsuyoshi Okada, Naomi Hasegawa, et al.
Pageof 25

Showing results (221-230 of 249) with videos related to

Sort By:
Pageof 25
Sleep Medicine|December 7, 2021
Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide studyRyuji Furihata, Rei Otsuki, Naomi Hasegawa, et al.
Bjpsych Open|November 20, 2018
Predictive factors for hyperglycaemic progression in patients with schizophrenia or bipolar disorderIchiro Kusumi, Yuki Arai, Ryo Okubo, et al.
BMC Psychiatry|June 28, 2023
Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment projectNaoki Hashimoto, Norio Yasui-Furukori, Naomi Hasegawa, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 6, 2026
Optimizing multi-site schizophrenia differentiation: MRI harmonization with 20 controls per scanner in a study of 3560 subjects across 15 MRI scannersNaoki Hashimoto, Kiyotaka Nemoto, Masaki Fukunaga, et al.
Neuropsychopharmacology Reports|July 1, 2020
Prescription patterns in patients with schizophrenia in Japan: First-quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" projectKayo Ichihashi, Hikaru Hori, Naomi Hasegawa, et al.
The International Journal of Neuropsychopharmacology|June 20, 2022
Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide StudyShinichiro Ochi, Hiromi Tagata, Naomi Hasegawa, et al.
Biological Psychiatry|February 16, 2016
Pharmacogenomic Study of Clozapine-Induced Agranulocytosis/Granulocytopenia in a Japanese PopulationTakeo Saito, Masashi Ikeda, Taisei Mushiroda, et al.
Neuropsychopharmacology Reports|November 29, 2022
Satisfaction with web-based courses on clinical practice guidelines for psychiatrists: Findings from the "Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)" projectHitoshi Iida, Tsuyoshi Okada, Kiyotaka Nemoto, et al.
Asian Journal of Psychiatry|January 20, 2022
The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE projectKayo Ichihashi, Yoshitaka Kyou, Naomi Hasegawa, et al.
Journal of Clinical Psychopharmacology|May 22, 2023
Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in JapanToshiaki Onitsuka, Tsuyoshi Okada, Naomi Hasegawa, et al.
Pageof 25